Barrie, Elizabeth S.
Pinsonneault, Julia K.
Sadee, Wolfgang
Hollway, Jill A.
Handen, Benjamin L.
Smith, Tristram
Eugene Arnold, L.
Butter, Eric
Hansen-Kiss, Emily
Herman, Gail E.
Aman, Michael G.
Funding for this research was provided by:
National Institute of General Medical Sciences (U01GM092655)
Center for Clinical and Translational Science, Ohio State University (UL1 RR025755)
National Institute of Mental Health (5R01MH079080, 5R01MH079082-05, 5R01 MH083247)
Eli Lilly and Company
National Center for Research Resources (UL1 RR024160, UL1TR001070)
National Center for Advancing Translational Sciences (FA7014-09-2-0004)
U.S. Air Force (FA8650-12-2-6359)
Article History
First Online: 5 March 2018
Compliance with Ethical Standards
:
: This work was supported by grants from: the National Institute of General Medical Sciences (U01GM092655), Center for Clinical and Translational Science at The Ohio State University (ARRA Pilot Project UL1 RR025755 project 60023888), National Institute of Mental Health to Ohio State University (5R01MH079080), University of Pittsburgh (5R01MH079082–05), and University of Rochester (5R01 MH083247), by Eli Lilly and Co., who provided atomoxetine and placebo, the National Center for Research Resources [University of Rochester CTSA (UL1 RR024160), Ohio State University CTSA (UL1TR001070)] and the National Center for Advancing Translational Sciences of the National Institutes of Health and the United States Air Force Department of Defense (FA7014–09–2-0004 and FA8650–12–2-6359). We are grateful to all the families participating in the CORA registry. The views and opinions expressed in this article are those of the author(s) and do not reflect official policy or position of the National Institutes of Health (NIH), United State Air Force, Department of Defense, or US Government. The use of product(s) and/or manufacturer name(s) is added for clarification only; in no way implies endorsement by the authors, USAF, or DoD of the product(s) or manufacturer(s). The funders have not imposed any restrictions on free access to or publication of the research data.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: This study was approved by the institutional review boards at all sites; parents/legal guardians of all participants signed informed consent documents, and children assented if able to do so.
: Dr. Elizabeth Barrie declares that she has no conflict of interest.Dr. Julia K. Pinsonneault received research funding from the Center for Clinical and Translational Science at The Ohio State University.Dr. Wolfgang Sadee received research funding from the National Institute of General Medical Sciences.Dr. Jill Hollway has received research contracts from Forest Research Institute, Supernus Pharmaceuticals, Sunovion Pharmaceuticals, Young Living Essential Oils, and Hoffman-La-Roche.Dr. Tristram Smith has received research funding from the National Center for Research Resources and the National Institute of Mental Health.Dr. Benjamin Handen has received research funding from Curemark, Autism Speaks, Eli Lilly and Co., Roche and the National Institute of Mental Health.Dr. L. Eugene Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, and YoungLiving (as well as NIH and Autism Speaks), has consulted with Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, and received travel support from Noven.Dr. Eric Butter has received research funding from CogState, Bracket, Autism Speaks, the Simons Foundation, and Roche.Ms. Emily Hansen-Kiss, LGC declares that she has no conflict of interest.Dr. Gail E. Herman has received research funding from the National Center for Advancing Translational Sciences of the National Institutes of Health and the United States Air Force Department of Defense.Dr. Michael Aman has received research contracts, consulted with, served on advisory boards, or done investigator training for Aevi Genomic Medicine, AMO Pharma, CogState, Inc.; CogState Clinical Trials, Ltd.; Coronado Biosciences; Forest Research; Hoffman-La Roche; Johnson and Johnson; Lumos Pharma, MedAvante, Inc.; Ovid Therapeutics, ProPhase LLC; and Supernus Pharmaceuticals. He also received research funding from the National Institute of Mental Health, and the Ohio State University CTSA.